A pre-transplant screening work-up of donors for allogeneic hematopoietic stem cell transplantation (HSCT) is essential. Inadvertent transmission of malignancy from donors with subclinical diseases to recipients has been reported recently in several cases. A 49-year-old male was diagnosed with acute myeloid leukemia. He underwent a course of induction chemotherapy and achieved cytogenetic complete remission (CR). He was treated with an additional cycle of consolidation chemotherapy followed by full matched sibling allogeneic HSCT due to an additional deletion in 9q known as an adverse prognostic factor. Post transplantation bone marrow biopsy revealed molecular CR, but conventional cytogenetics identified the presence of 46,XY,t(1:2)(p32:q35). A cytogenetic analysis of the donor graft specimen revealed t(1:2). We confirmed the donor origin of t(1:2). We report the first case of a person with constitutional t(1;2) serving as a stem cell donor.
INTRODUCTION
Allogeneic hematopoietic stem cell transplantation (HSCT) is frequently performed in patients with hematologic malignancies.
A pre-transplant screening work-up of donors for allogeneic HSCT is essential in an effort to minimize risks to the recipient and to protect the donor. Recommended donor work-ups include a complete medical history and physical examination, blood workup (complete blood count, differential counts, complete panel, lactate dehydrogenase, prothrombin time/partial thromboplastin time, blood type, human leukocyte antigen (HLA) testing, and β-human chorionic gonadotropin), infectious disease testing (cytomegalovirus immunoglobulin G, Epstein-Barr virus, human immunodeficiency virus-1 and -2 antibody, human immunodeficiency virus antigen nucleic acid amplification test, human T cell leukemia virus-1 and -2 antibody, West Nile virus nucleic acid amplification test, hepatitis B surface antigen, hepatitis B core antibody, hepatitis C virus nucleic acid amplification test, rapid plasma reagin, and type and screen), urinalysis, chest X-ray, and/or electrocardiography. Despite routine screening, inadvertent transmission of various malignant and nonmalignant diseases from donor to recipient has been reported in several cases [1] [2] [3] . Kiss et al. [4] suggested that bone marrow aspirates, as part of routine donor assessment for allogeneic HSCT, reveal the presence of occult hematological malignancies in otherwise asymptomatic individuals. However, routine bone marrow and karyotype examination of donors is still not carried out because of cost-ineffectiveness and discomfort for the donor. We report the case of a patient with constitutional cytogenetic abnormality transmitted from an allogeneic stem cell donor. In addition to the transmission of malignant disease, donors with constitutional cytogenetic abnormalities have also been rarely reported. Manola et al. [6] reported two persons with mosaic Turner syndrome serving as stem cell donors. These donors had no overt symptoms; however, they had the potential to develop diabetes, osteoporosis, and immunologic disturbances. Frey et al. [7] reported a person with trisomy 8 who served as a stem cell donor.
CASE REPORT
Given the rarity of trisomy 8 mosaicism (T8m), it is difficult to assess whether the presence of this constitutional abnormality is associated with an increased risk of hematologic malignancies. Several people with T8m have been reported to develop hematologic malignancies [8] [9] [10] .
Our report is a case of inadvertent transmission of a donor's constitutional t(1;2)(p32;q35) to a recipient. The donor with t(1;2) (p32;q35) received a clean bill of health, and there was no family history. His condition was considered an inclusion criterion for stem cell donation. In Korea, routine screening of adult donors http://jsms.sch.ac.kr does not include a bone marrow examination, so we did not know that he had constitutional cytogenetic abnormalities. The t(1;2) (p32;q35) aberration is a very rare cytogenetic abnormality, and its exact role is unclear. Several cases have been reported correlating chromosome 1 band p32 (1p32) aberrations and T lymphoblastic leukemia/lymphoma [11] . However, it is difficult to assess whether the presence of this constitutional abnormality is associated with an increased risk of malignancy.
Constitutional chromosomal abnormalities are inherited from a carrier parent or are present in all tissues after occurring de novo in gametes. Data from literature reviews have consistently shown a <1% incidence of all constitutional aberrations in hematologic malignancies, similar to that found in the general population [12, 13] .
These results suggest that persons with constitutional chromosomal abnormalities do not have an increased risk of hematologic malignancy. However, there are some reports of constitutional translocations with breakpoints similar to leukemia-associated specific breakpoints in hematologic malignancy [14] . Patients treated with allogeneic HSCT are not representative of the general population, as they are exposed to radiotherapy, chemotherapy, and even immune dysfunction (T cell depletion, HLA mismatch, GVHD, and immunosuppressive therapy); these are risk factors for acquiring genetic mutations. The hypothesis proposed by Knudson et al. [15] suggests that two mutational events are required for the development of cancer; the first step is a constitutional event and the second is an acquired genetic mutation. Inheriting constitutional t(1;2)
can serve as a foundation for the development of secondary cancer after allogeneic HSCT.
These results suggest the importance of bone marrow and karyotype examination of donors. A cytogenetic study of all donors would allow the detection of abnormal clones and prevent transmission to other persons. In fact, few centers perform routine bone marrow aspirates as part of the donor work-up. However, to carry out these examinations systematically in all donors would be cost-ineffective, and it would be uncomfortable for the donors.
Kiss et al. [4] asserted that more screening investigations, including bone marrow aspiration, might be reasonable to investigate for occult hematological malignancies prior to stem cell donation, particularly in older donors and donors with potential for familial malignancies. We suggest that more extensive donor screening, including bone marrow aspiration with karyotyping, may be reasonable if the recipient is young. Young patients have more time to be exposed to hazardous environments that can cause acquired genetic alterations. A less invasive method of examination with a simple procedure including detection of constitutional cytogenetic change by using oral mucosal cells could also be considered.
We report the first case of a person with constitutional t(1;2) serving as a stem cell donor. Although one case is insufficient to support the need for routine bone marrow biopsy prior to transplantation, the need for precise evaluation of the incidence, prognosis, and outcome of donor-transmitted chromosomal abnormalities is suggested. A nationwide registry of donor-transmitted abnormalities is necessary to allow for possible changes in donor screening.
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